Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9
J. H. M. Schellens(The Netherlands Cancer Institute), A-R Hanauske(TUM Klinikum), S. Monfardini, Nikolaos Pavlidis(University Hospital of Ioannina), F. Calabresi, Luc Dirix(GZA Ziekenhuizen Campus Sint-Augustinus), Jim Cassidy(University of Glasgow), Eugène Cox(The Netherlands Cancer Institute), Johannes Wolff(The University of Texas MD Anderson Cancer Center), Ron Epelbaum(University of Bern), Jaap Verweij(Deutz (Germany)), J. Wanders(Eisai (United Kingdom)), Robert Paridaens(Cornell University), Walter J. Loos(Rotterdam University of Applied Sciences), P Dombernowsky(Unknown)
Cited by 13
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cremophor EL
|European Journal of Cancer|2001|1.6k